GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Return-on-Tangible-Asset

Ambrx Biopharma (Ambrx Biopharma) Return-on-Tangible-Asset : -70.35% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ambrx Biopharma's annualized Net Income for the quarter that ended in Jun. 2023 was $-132.51 Mil. Ambrx Biopharma's average total tangible assets for the quarter that ended in Jun. 2023 was $188.37 Mil. Therefore, Ambrx Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was -70.35%.

The historical rank and industry rank for Ambrx Biopharma's Return-on-Tangible-Asset or its related term are showing as below:

AMAM' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -85.56   Med: -48.24   Max: -27.43
Current: -33.63

During the past 4 years, Ambrx Biopharma's highest Return-on-Tangible-Asset was -27.43%. The lowest was -85.56%. And the median was -48.24%.

AMAM's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -40.01 vs AMAM: -33.63

Ambrx Biopharma Return-on-Tangible-Asset Historical Data

The historical data trend for Ambrx Biopharma's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Return-on-Tangible-Asset Chart

Ambrx Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
-85.56 -27.43 -46.91 -49.56

Ambrx Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Asset Get a 7-Day Free Trial -84.83 -84.60 -118.24 -76.55 -70.35

Competitive Comparison of Ambrx Biopharma's Return-on-Tangible-Asset

For the Biotechnology subindustry, Ambrx Biopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambrx Biopharma's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Ambrx Biopharma's Return-on-Tangible-Asset falls into.



Ambrx Biopharma Return-on-Tangible-Asset Calculation

Ambrx Biopharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-77.996/( (193.057+121.727)/ 2 )
=-77.996/157.392
=-49.56 %

Ambrx Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-132.512/( (121.727+255.009)/ 2 )
=-132.512/188.368
=-70.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data.


Ambrx Biopharma  (NAS:AMAM) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Ambrx Biopharma Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambrx Biopharma (Ambrx Biopharma) Business Description

Traded in Other Exchanges
Address
10975 North Torrey Pines Road, La Jolla, CA, USA, 92037
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor director, officer: President and CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan 10 percent owner WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd. 10 percent owner C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg director C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans director C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando officer: Chief Operating Officer C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116